Answers are grounded in this paper and cite their sources.
Recombinant AAV injection improved diastolic dysfunction and cardiac function in transgenic mice with HFpEF, suggesting therapeutic potential of cTnI-C27 peptide.
Diastolic heart failure, i.e., heart failure with preserved ejection fraction (HFpEF) constitutes more than half of heart failure cases and lacks effective treatment. The conserved C-terminal end segment of cardiac troponin I (cTnI) functions in regulating cardiac muscle relaxation. Our previous studies found that isolated cTnI C-terminal end 27 amino acids peptide (cTnI-C27) preserves an intrinsic 3D structure same as that in intact cTnI and retains binding affinity for tropomyosin with a myofilament Ca 2+ -desensitization effect when added to skinned cardiac muscle sections (PMID: 31505197; 33814345). To establish the functionality of cTnI-C27 peptide for clinical applications as a therapeutic reagent to correct myocardial diastolic dysfunction and treat HFpEF, we further developed in vivo delivery and cardiac muscle-specific expression of cTnI-C27 peptide to test the therapeutic effect on HFpEF mice. A recombinant adeno-associated virus (AAV9) vector was constructed using an enhanced cardiac troponin T gene promoter to express a cDNA encoding human cTnI-C27 peptide. The recombinant AAV was i.v. injected into wild-type (WT) and transgenic mice expressing a hypertrophic cardiomyopathy (HCM) alpha-tropomyosin mutant (Tm-E180G). PCR confirmed the delivery of cTnI-C27 AAV into the mouse cardiac muscle. Echocardiography studies detected significant effects of the cardiac muscle-specific expression of HcTnI-C27 peptide on cardiac function in vivo from 2.5 to 14 days post-AAV injection, showing increased left ventricular diastolic volume and an effective correction of the supercontractivity/HFpEF phenotype of Tm-E180G hearts. Ex vivo working heart studies 14 days post-AAV treatment confirmed the improved myocardial diastolic function in WT and Tm-E180G hearts, supporting the therapeutic efficacy of cTnI-C27 peptide on correcting diastolic dysfunction of cardiac muscle for use in the treatment of HFpEF in HCM.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: